A new study posts some astonishing results. Some thoughts:
- It was sponsored and is being trumpeted by a BCMA Vendor. The potential for internal bias is high.
- Although all studies of new drugs come from manufactures of the drug, they need to adhere to FDA scrutiny. It would be great to have this study come under peer review.
- If anyone has contact info or pull with Intellidot, they should be encouraged to submit it to a peer review journal.
- 39 incidents out of 2,389 observations averted does not seem like a lot to me (1.6%). Although the argument is that if it was you or your child involved you would want the BCMA technology. It would also be interesting to calculate the ROI per incident avoided.
No comments:
Post a Comment